Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafamidis in Transthyretin Amyloid Polyneuropathy
NCT01435655Phase 3Completed
- Sponsor
- Pfizer
- Start
- Nov 2011
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tafamidis in transthyretin familial amyloid polyneuropathy (TTR-FAP), sponsored by Pfizer. Primary endpoint: Transthyretin Stabilization at 8 weeks. Started Nov 2011; status: completed.
02
Drugs
tafamidis
03
Conditions
transthyretin familial amyloid polyneuropathy (TTR-FAP)
Beyond the preview
Go deeper on NCT01435655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01435655.